ClinicalTrials.gg
CompletedNCT02019719Updated Feb 12, 2018Results posted

Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease

A Phase 2 interventional study of GSK1278863 and Placebo in Anaemia, sponsored by GlaxoSmithKline. Completed at 21 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-02-12.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
97
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.

Enrollment
14th of 30
97 · median 76
Started
2013
with 2 others
Phase 2
10 of 30
none open now
Registered
8th of 30
by date
Lead sponsor
28 of 30
GlaxoSmithKline

Among the 30 studies testing GSK1278863 in Anemia, this one is the 14th largest by enrollment, is one of 3 that started in 2013, is one of 10 in phase 2, and was the 8th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:

About GSK1278863

GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing GSK1278863 in Anemia, or all of them as a file.
02

Study summary

This study aims to characterize the relationship between dose of GSK1278863 and hemoglobin (Hgb) response in hemodialysis-dependent (HDD) subjects with anemia associated with chronic kidney disease (CKD). It is anticipated that the data generated will enable selection of the starting dose(s) and optimize dose adjustment regimen(s) for Phase 3 clinical trials. This study will consist of a screening phase of 3-9 weeks, a 4-week treatment phase and a follow-up visit approximately 4 weeks after completing treatment.

03

Conditions studied

  • Anaemia

Keywords

  • Hemodialysis
  • GSK1278863
  • Pharmacokinetics
  • Erythropoiesis Stimulating Agents
  • Chronic Kidney Disease
  • Hemoglobin
  • Recombinant Erythropoietin
  • Prolyl Hydroxylase Inhibitor
  • Anemia
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age (Informed concent): Japanese >=20 years of age
  • Gender (Screening 2 verification only): Female and male
  • Females: must be of , and must agree to use one of the approved methods from Screening 2 until completion of the Follow-up Visit. OR Of non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or defined as 12 months of spontaneous amenorrea [in questionable cases a blood sample with simultaneous follicle stimulating hormone 23.0 - 116.3 million international units (MIU)/millilitre (mL) and estradiol \<= 10 picograms (pg)/mL is confirmatory]. Females on hormone replacement therapy (HRT) whose menopausal status is in doubt will be required to use one of the approved contraception methods if they wish to continue their HRT during the study. Otherwise they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment. For most forms of HRT, at least 2 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method. Males: must agree to use one of the approved contraceptive methods from the time of Screening 2 until completion of the Follow-up Visit.
  • interval (QTc) (Screening 2 verification only): Bazett's Correction of QT Interval (QTcB) \<470 milliseconds (msec) or QTcB \<480 msec in subjects with bundle branch block. There is no QTc inclusion criterion for a subject with a predominantly paced rhythm.
  • Dialysis frequency: On hemodialysis (HD) three times weekly for at least 8 weeks prior to Screening 2 through Day 1.
  • Dialysis adequacy (Screening 2 only): A single-pool Kt/Vurea of 1.2 based on a historical value obtained within the prior month in order to ensure the adequacy of dialysis. If Kt/Vurea is not available, then an average of the last 2 values of urea reduction ratio (URR) of at least 65%.
  • : Target stable Hgb between 9.5-12.0 g/dL at screening.
  • Stable erythropoiesis-stimulating agent (ESA) dose (Screening 2 only): Using the same ESA (epoetins or their biosimilar, or darbepoietin) with total weekly doses that varied by no more than 50% during the 4 weeks prior to Screening 2.
  • Iron replacement therapy: Subjects may be on stable maintenance oral or intravenous (IV) (\<100 milligrams [mg]/week) iron supplementation. If subjects are on oral or IV iron, then doses must be stable for the 4 weeks prior to Screening 2, and Screening 2 through Week 4.

Exclusion criteria

Exclusion Criteria:

  • Dialysis modality: Planned change from HD to peritoneal dialysis within the study time period.
  • Renal transplant: Renal transplant anticipated or scheduled within the study time period.
  • High ESA dose (Screening 2 verification only): As defined by an epoetin dose of >=360 IU/kilograms (kg)/week IV or darbepoetin dose of >=1.8 micrograms (μg)/kg/week IV within the prior 8 weeks through Screening 2.
  • methoxy polyethylene glycol epoetin beta (Screening 2 verification only): Use of methoxy polyethylene glycol epoetin beta within the prior 8 weeks through Screening 2.
  • Vitamin B12: At or below the lower limit of the reference range
  • Folate: \<2.0 nanograms (ng)/mL (\<4.5 nanomoles [nmol]/liters [L])
  • Iron status: Ferritine \<100 ng/mL (\<100 μg/L) AND Transferrin saturation (TSAT) \<20%
  • Myocardial infarction or acute coronary syndrome: Within the 8 weeks prior to Screening 2 through Day 1.
  • Stroke or : Within the 8 weeks prior to Screening 2 through Day 1.
  • Heart failure: Class III/IV heart failure, as defined by the (NYHA) functional classification system or symptomatic right heart failure diagnosed prior to Screening 2 through Day 1.
  • Hypertension: Defined using pre-dialysis vitals of diastolic blood pressure >100 mmHg or systolic blood pressure >170 mmHg.
  • Thrombotic disease: History of thrombotic disease (e.g., venous thrombosis such as deep vein thrombosis or pulmonary embolism, or arterial thrombosis such as new onset or worsening limb ischemia requiring intervention), except vascular access thrombosis, within the 8 weeks prior to Screening 2 through Day 1
  • Eyes: History of proliferative retinopathy requiring treatment within the prior 12 months or macular edema requiring treatment..
  • Inflammatory disease: Active chronic inflammatory disease that could impact erythropoiesis (e.g., scleroderma, systemic lupus erythematosis, rheumatoid arthritis, celiac disease) diagnosed prior to Screening 2 through Day 1.
  • Hematological disease: Any hematological disease including those affecting , white or red blood cells (e.g. sickle cell anemia, myelodysplastic syndromes, hematological , myeloma, hemolytic anemia and thalassemia), coagulation disorders (e.g., antiphospholipid syndrome, Protein C or S deficiency), or any other cause of anemia other than renal disease diagnosed prior to Screening 2 through Day 1.
  • Liver disease: Current liver disease, known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones) or evidence at Screening of abnormal liver function tests [ (ALT) or aspartate transaminase (AST) >2.0 x (ULN) or total > 1.5 x ULN]; or other hepatic abnormalities that in the opinion of the investigator (subinvestigator) would preclude the subject from participation in the study.
  • Major surgery: Major surgery (excluding vascular access surgery) within the prior 8 weeks, within the Screening 2 to Day 1 or planned during the study.
  • Transfusion: Blood transfusion within the prior 8 weeks, within the Screening 2 to Day 1 or an anticipated need for blood transfusion during the study.
  • Gastrointestinal (GI) bleeding: Evidence of actively bleeding peptic, duodenal, or esophageal ulcer disease OR GI bleeding within the 8 weeks prior to Screening 2 through Day 1.
  • Acute infection: Clinical evidence of acute infection or history of infection requiring IV antibiotic therapy within 8 weeks prior to Screening 2 through Day 1.
  • Malignancy: Subjects with a history of malignancy within the prior 5 years, who receiving treatment for cancer, or who have a strong family history of cancer (e.g., familial cancer disorders); with the exception of squamous cell or basal cell carcinoma of the skin that has been definitively treated prior to Screening 2 through Day 1.
  • Severe allergic reactions: History of severe allergic or anaphylactic reactions or to in the product
  • Drugs and supplements: Use of any prescription or non-prescription drugs or dietary supplements that are prohibited from Screening 2 until the Follow-up Visit.
  • Prior investigational product exposure: The Subject has participated in a clinical trial and has received an experimental investigational product within the prior 30 days from Screening 2 through Day 1.
  • Pregnancy or lactation: Pregnant females as determined by positive serum Human Chorionic Gonadotrophin (hCG) test (Screening 2 only) OR women who are lactating at Screening 2 and/or Day 1 or during the trial.
  • Other conditions: Any other condition, clinical or laboratory abnormality, or examination finding that the Investigator would consider inappropriate to participate in the study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
97 participants (actual)

Study arms

  • Experimental
    GSK1278863 4 milligrams (mg)

    Subjects will receive GSK1278863 4 mg once daily for 4 weeks

    Drug: GSK1278863

  • Experimental
    GSK1278863 6 mg

    Subjects will receive GSK1278863 6 mg once daily for 4 weeks

    Drug: GSK1278863

  • Experimental
    GSK1278863 8 mg

    Subjects will receive GSK1278863 8 mg once daily for 4 weeks

    Drug: GSK1278863

  • Experimental
    GSK1278863 10 mg

    Subjects will receive GSK1278863 10 mg once daily for 4 weeks

    Drug: GSK1278863

  • Placebo comparator
    Placebo

    Subjects will receive placebo once daily for 4 weeks

    Drug: Placebo

Interventions

  • GSK1278863 will be supplied as film coated tablets for oral administration containing 1 mg, 2 mg, or 5 mg of GSK1278863.

  • DrugPlacebo

    Film coated tablets of GSK1278863 matching placebo for oral administration.

06

What researchers measure

Primary outcomes

  1. Change From Baseline (CFB) in Hemaglobin (Hgb) at Week 4

    Baseline was defined as the value on Day 1. CFB was calculated by subtracting the baseline value from the post-dose value at Week 4. To model the dose-response relationship a four-parameter Emax model was used. E0 is the expected Hgb change from Baseline for a participant receiving placebo and experiencing the average Hgb Baseline observed in the study. Emax is the expected Hgb change from Baseline for a participant receiving the highest dose above which no further increase in response can be achieved. ED50 is the dose that attains the intermediate response. Gamma is the slope parameter. Minimal Effective Dose (MED) is defined as the smallest dose that achieves a placebo-corrected change of 0.5 g/dL over Week 4. Target dose (TD) is defined as the dose that achieves a placebo-corrected 1.0 g/dL change over Week 4. Maximum Acceptable Dose (MAD) is defined as the dose that achieves a placebo-corrected 2.0 g/dL change over Week 4.

    Time frame: Baseline (Day 1) and Week 4

Secondary outcomes

  1. CFB in Hgb Upto Week 8

    Hgb assessments were performed at Baseline, Week 1, Week 2, Week 3, W eek4/Early withdrawal and Week 8 (follow-up) based on central laboratory (Quest diagnosis). Baseline was defined as the value on Day 1. CFB was calculated by subtracting the Baseline value from the post-dose value at Week 4.

    Time frame: Baseline (Day 1) Upto Week 8

  2. Number of Participants Who Achieved Hgb Response at Week 4

    Hgb response was defined as achieving an increase of at least 0.5 g/dL, 1.0 g/dL, 1.5 g/dL, and 2.0 g/dL in Hgb. The number of participants with Hgb response: Hgb increase \<-1.0, Hgb increase -1.0 -\< -0.5, Hgb increase -0.5 -\< 0.5, Hgb increase 0.5 -\< 1.0 and Hgb increase \>=1.0 have been presented.

    Time frame: Week 4

  3. Percentage of Participants Who Achieved Hgb Response at Week 4

    Hgb response was defined as achieving an increase of at least 0.5 g/dL, 1.0 g/dL, 1.5 g/dL, and 2.0 g/dL in Hgb. The percentage of participants with Hgb response: Hgb increase \<-1.0, Hgb increase -1.0 -\< -0.5, Hgb increase -0.5 -\< 0.5, Hgb increase 0.5 -\< 1.0 and Hgb increase \>=1.0 have been presented.

    Time frame: Week 4

  4. Number of Participants Who Reached Pre-defined Hgb Stopping Criteria

    Hgb stopping criteria was defined as: (1) Hgb \<7.5 g/dL (2) 7.5 \<= Hgb \<1 3.0 g/dL and \>2 g/dL Hgb change over 2W (3) Hgb \>=13.0 g/dL. The number of participants who reached pre-defined Hgb stopping criteria have been presented.

    Time frame: Upto Week 4

  5. Maximum Observed CFB in Erythropoietin (EPO) Upto Week 4

    Blood samples for EPO were collected on Day 1 (pre-dose), Week 2 (collected approx 6-12 hours post-dose on arrival and after 1, 2 and 3 hours) and Week 4 (pre-dose and 3 hours post-dose). Maximum observed value meant maximum value between Week 1 and Week 4. Baseline was defined as the value on Day 1. Maximum observed CFB was calculated by subtracting the Baseline value from the maximum observed value between Week 1 and Week 4.

    Time frame: Baseline (Day 1) Upto Week 4

  6. Maximum Observed Percent CFB in Peak Vascular Endothelial Growth Factor (VEGF) Upto Week 4

    Blood samples for VEGF were collected on Day 1 (pre-dose), Week 2 (collected approximately 6-12 hours post-dose on arrival and after 1, 2 and 3 hours) and Week 4 (pre-dose and 3 hours post-dose). Maximum observed value meant maximum value between Week 1 and Week 4. Baseline was defined as the value on Day 1. Maximum observed percent CFB was calculated as 100 multiplied by the maximum observed exponential mean change on a log scale minus 1.

    Time frame: Baseline (Day 1) Upto Week 4

  7. Percent CFB in Hepcidine Upto Week 4

    Blood samples for hepcidine were collected on Day 1 (pre-dose), Week 2 (collected approximately 6-12 hours post-dose) and Week 4 (pre-dose). Baseline was defined as the value on Day 1. Percent CFB was calculated as 100 multiplied by the exponential mean change on a log scale minus 1.

    Time frame: Baseline (Day 1) Upto Week 4

  8. CFB in Ferritin at Week 4

    Ferritin was used as marker of iron metabolism and utilization. Baseline was defined as the value on Day 1. CFB was calculated by subtracting the Baseline value from the post dose value at Week 4.

    Time frame: Baseline (Day 1) and Week 4

  9. CFB in Total Iron Binding Capacity [TIBC], Unbound Iron Binding Capacity [UIBC] and Iron at Week 4

    TIBC, UIBC and Iron were used as marker of iron metabolism and utilization. Baseline was defined as the value on Day 1. CFB was calculated by subtracting the Baseline value from the post-dose value at Week 4.

    Time frame: Baseline (Day 1) and Week 4

  10. CFB in Transferrin at Week 4

    Transferrin was used as marker of iron metabolism and utilization. Baseline was defined as the value on Day 1. CFB was calculated by subtracting the Baseline value from the post-dose value at Week 4.

    Time frame: Baseline (Day 1) and Week 4

  11. Percent CFB in Transferrin Saturation (TS) at Week 4

    TS was used as marker of iron metabolism and utilization. Baseline was defined as the value on Day 1. Percent CFB was calculated as 100 multiplied by the exponential mean change on a log scale minus 1.

    Time frame: Baseline (Day 1) and Week 4

  12. Plasma Pharmacokinetic Concentration of GSK1278863 and Metabolites (M) at Week 4

    Blood samples for plasma pharmacokinetic analysis were collected at Week 4 (pre-dose, 1, 2, 3 hours post-dose). Individual plasma GSK1278863 and M-GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531401, GSK2531403 concentrations have been presented.

    Time frame: Week 4

  13. Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) on Therapy

    An AE is defined as any untoward medical occurrence in clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. A SAE is defined as any AE which results in death; is life-threatening; requires participant hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event.

    Time frame: Upto Week 4

  14. Number of Participants With Chemistry and Hematology Data of Potential Clinical Importance (PCI) Upto Week 4

    The PCI range was as follows: alkaline phosphates \>= 3 times upper limit of normal range \[ULRR\]), potassium (\>0.5 millimoles/liter below the LLRR or \>1.0 millimoles/liter above the ULRR), phosphate (\>0.323 millimoles/liter above ULRR or below lower limit reference range \[LLRR\]), glucose (\<3.9 or \>22 millimoles/liter), magnesium (\<LLRR or \> 0.3 milimoles/liter above ULRR), lymphocytes \<0.5x LLRR, neutrophils (\<0.5 times LLRR), platelets (80 or \>500 times giga/liter), platelets (80 or \>500 times giga/liter) and leukocytes \>1 x giga/liter below the LLRR or \>5 x GI/L above the ULRR. The participants who had PCI values higher and lower than the reference range have been presented.

    Time frame: Upto Week 4

  15. Number of Participants With Vital Signs Parameters Systolic and Diastolic Blood Pressure (SBP,DBP) of PCI Upto Week 4

    Vital signs SBP and DBP were recorded pre-dialysis and post-dialysis. Measurements were taken from the participant while in a seated position or semi-supine in the dialysis chair. PCI range for SBP was \< 85 or \> 170 and for DBP was \< 45 or \> 100 millimeters of mercury. Participant's with values high and low from the PCI range have been presented.

    Time frame: Upto Week 4

  16. Number of Participants With Vital Sign Parameter Heart Rate (HR) of PCI Upto Week 4

    Vital sign HR was recorded pre-dialysis and post-dialysis. Measurements were taken from the participant while in a seated position or semi-supine in the dialysis chair. PCI range for HR was \< 40 or \> 110 beats per minute. Participant's with values higher than the PCI range have been presented.

    Time frame: Upto Week 4

  17. Number of Participants With Abnormal Electrocardiogram (ECG) Findings Upto Week 4

    Full 12-lead ECGs included heart rate, PR, QRS, QT and QTc intervals. Measurements were taken from the participant while in a supine position. ECGs were performed consistently either before or after dialysis throughout the study. ECG abnormalities characterized as abnormal-not clinically significant (A-NCS) and abnormal-clinically significant (A-CS) upto W4 have been presented.

    Time frame: Upto Week 4

07

Results

Posted Feb 12, 2018

Participant flow

This was a study to evaluate dose-response of GSK1278863 in approximately 95 Japanese Hemodialysis-dependent (HDD) participants with anemia associated with Chronic Kidney Disease (CKD) conducted across 21 centers in Japan from 05 November 2013 to 06 August 2014.

Participant flow — Overall Study
MilestonePlaceboGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mg
Started1919201920
Completed1318201718
Not completed61022
Withdrew: Adverse event10011
Withdrew: Protocol violation11000
Withdrew: Protocol defined stopping criteria20011
Withdrew: Physician decision20000

Outcome measures

PrimaryChange From Baseline (CFB) in Hemaglobin (Hgb) at Week 4

Baseline was defined as the value on Day 1. CFB was calculated by subtracting the baseline value from the post-dose value at Week 4. To model the dose-response relationship a four-parameter Emax model was used. E0 is the expected Hgb change from Baseline for a participant receiving placebo and experiencing the average Hgb Baseline observed in the study. Emax is the expected Hgb change from Baseline for a participant receiving the highest dose above which no further increase in response can be achieved. ED50 is the dose that attains the intermediate response. Gamma is the slope parameter. Minimal Effective Dose (MED) is defined as the smallest dose that achieves a placebo-corrected change of 0.5 g/dL over Week 4. Target dose (TD) is defined as the dose that achieves a placebo-corrected 1.0 g/dL change over Week 4. Maximum Acceptable Dose (MAD) is defined as the dose that achieves a placebo-corrected 2.0 g/dL change over Week 4.

Time frame:
Baseline (Day 1) and Week 4
Reported as:
Least squares mean · grams/deciliter (g/dL)
Change From Baseline (CFB) in Hemaglobin (Hgb) at Week 4
grams/deciliter (g/dL)PlaceboGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mg
Change From Baseline (CFB) in Hemaglobin (Hgb) at Week 4-1.52 ± 0.212-0.29 ± 0.200-0.02 ± 0.1930.60 ± 0.2020.92 ± 0.196
Statistical analysis
  • Placebo vs GSK1278863 4 mg vs GSK1278863 6 mg vs GSK1278863 8 mg vs GSK1278863 10 mg · E0 (g/dl): -1.37 · 95% CI -1.72 to -1.03Posterior median and 95% credibility intervals were estimated using Bayesian methods.
  • Placebo vs GSK1278863 4 mg vs GSK1278863 6 mg vs GSK1278863 8 mg vs GSK1278863 10 mg · Ed50 (mg): 21.88 · 95% CI 9.99 to 42.64Posterior median and 95% credibility intervals were estimated using Bayesian methods.
  • Placebo vs GSK1278863 4 mg vs GSK1278863 6 mg vs GSK1278863 8 mg vs GSK1278863 10 mg · Emax (g/dl): 5.88 · 95% CI 3.20 to 8.61Posterior median and 95% credibility intervals were estimated using Bayesian methods.
  • Placebo vs GSK1278863 4 mg vs GSK1278863 6 mg vs GSK1278863 8 mg vs GSK1278863 10 mg · Gamma: 1.13 · 95% CI 0.70 to 1.68Posterior median and 95% credibility intervals were estimated using Bayesian methods.
  • Placebo vs GSK1278863 4 mg vs GSK1278863 6 mg vs GSK1278863 8 mg vs GSK1278863 10 mg · Var: 0.66 · 95% CI 0.50 to 0.88Posterior median and 95% credibility intervals were estimated using Bayesian methods.
  • Placebo vs GSK1278863 4 mg vs GSK1278863 6 mg vs GSK1278863 8 mg vs GSK1278863 10 mg · Med (mg): 1.98 · 95% CI 0.75 to 3.41Posterior median and 95% credibility intervals were estimated using Bayesian methods.
  • Placebo vs GSK1278863 4 mg vs GSK1278863 6 mg vs GSK1278863 8 mg vs GSK1278863 10 mg · Td (mg): 3.90 · 95% CI 2.20 to 5.63Posterior median and 95% credibility intervals were estimated using Bayesian methods.
  • Placebo vs GSK1278863 4 mg vs GSK1278863 6 mg vs GSK1278863 8 mg vs GSK1278863 10 mg · Mad (mg): 8.65 · 95% CI 6.51 to 11.44Posterior median and 95% credibility intervals were estimated using Bayesian methods.
SecondaryCFB in Hgb Upto Week 8

Hgb assessments were performed at Baseline, Week 1, Week 2, Week 3, W eek4/Early withdrawal and Week 8 (follow-up) based on central laboratory (Quest diagnosis). Baseline was defined as the value on Day 1. CFB was calculated by subtracting the Baseline value from the post-dose value at Week 4.

Time frame:
Baseline (Day 1) Upto Week 8
Reported as:
Mean · g/dL
CFB in Hgb Upto Week 8
g/dLPlaceboGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mg
CFB at Week 1-0.34 ± 0.485-0.23 ± 0.374-0.35 ± 0.462-0.31 ± 0.481-0.17 ± 0.318
CFB at Week 2-0.79 ± 0.538-0.32 ± 0.449-0.32 ± 0.7800.01 ± 0.5860.24 ± 0.353
CFB at Week 3-1.14 ± 0.743-0.42 ± 0.658-0.34 ± 0.7760.21 ± 0.6920.37 ± 0.471
CFB at Week 4-1.31 ± 0.923-0.33 ± 0.754-0.22 ± 1.0080.34 ± 1.0690.51 ± 0.679
CFB at Week 8, Follow-up-1.20 ± 0.997-0.90 ± 0.953-0.38 ± 0.526-0.21 ± 1.218-0.34 ± 0.691
SecondaryNumber of Participants Who Achieved Hgb Response at Week 4

Hgb response was defined as achieving an increase of at least 0.5 g/dL, 1.0 g/dL, 1.5 g/dL, and 2.0 g/dL in Hgb. The number of participants with Hgb response: Hgb increase \<-1.0, Hgb increase -1.0 -\< -0.5, Hgb increase -0.5 -\< 0.5, Hgb increase 0.5 -\< 1.0 and Hgb increase \>=1.0 have been presented.

Time frame:
Week 4
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Hgb Response at Week 4
ParticipantsPlaceboGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mg
Hgb increase <-1.0114300
Hgb increase -1.0 -< -0.522210
Hgb increase -0.5 -< 0.5210876
Hgb increase 0.5 -< 1.001344
Hgb increase >=1.001469
SecondaryPercentage of Participants Who Achieved Hgb Response at Week 4

Hgb response was defined as achieving an increase of at least 0.5 g/dL, 1.0 g/dL, 1.5 g/dL, and 2.0 g/dL in Hgb. The percentage of participants with Hgb response: Hgb increase \<-1.0, Hgb increase -1.0 -\< -0.5, Hgb increase -0.5 -\< 0.5, Hgb increase 0.5 -\< 1.0 and Hgb increase \>=1.0 have been presented.

Time frame:
Week 4
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Hgb Response at Week 4
Percentage of participantsPlaceboGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mg
Hgb increase <-1.0732215——
Hgb increase -1.0 -< -0.51311106—
Hgb increase -0.5 -< 0.51356403932
Hgb increase 0.5 -< 1.0—6152221
Hgb increase >=1.0—6203347
SecondaryNumber of Participants Who Reached Pre-defined Hgb Stopping Criteria

Hgb stopping criteria was defined as: (1) Hgb \<7.5 g/dL (2) 7.5 \<= Hgb \<1 3.0 g/dL and \>2 g/dL Hgb change over 2W (3) Hgb \>=13.0 g/dL. The number of participants who reached pre-defined Hgb stopping criteria have been presented.

Time frame:
Upto Week 4
Reported as:
Count of participants · Participants
Number of Participants Who Reached Pre-defined Hgb Stopping Criteria
ParticipantsPlaceboGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mg
< 7.520000
7..5 -< 13.0 and >2 g/dL change00021
SecondaryMaximum Observed CFB in Erythropoietin (EPO) Upto Week 4

Blood samples for EPO were collected on Day 1 (pre-dose), Week 2 (collected approx 6-12 hours post-dose on arrival and after 1, 2 and 3 hours) and Week 4 (pre-dose and 3 hours post-dose). Maximum observed value meant maximum value between Week 1 and Week 4. Baseline was defined as the value on Day 1. Maximum observed CFB was calculated by subtracting the Baseline value from the maximum observed value between Week 1 and Week 4.

Time frame:
Baseline (Day 1) Upto Week 4
Reported as:
Mean · International units/liter
Maximum Observed CFB in Erythropoietin (EPO) Upto Week 4
International units/literPlaceboGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mg
Maximum Observed CFB in Erythropoietin (EPO) Upto Week 46.658 ± 4.541434.951 ± 28.271894.518 ± 122.4985151.012 ± 151.2964173.446 ± 226.7241
SecondaryMaximum Observed Percent CFB in Peak Vascular Endothelial Growth Factor (VEGF) Upto Week 4

Blood samples for VEGF were collected on Day 1 (pre-dose), Week 2 (collected approximately 6-12 hours post-dose on arrival and after 1, 2 and 3 hours) and Week 4 (pre-dose and 3 hours post-dose). Maximum observed value meant maximum value between Week 1 and Week 4. Baseline was defined as the value on Day 1. Maximum observed percent CFB was calculated as 100 multiplied by the maximum observed exponential mean change on a log scale minus 1.

Time frame:
Baseline (Day 1) Upto Week 4
Reported as:
Geometric mean · Percent change
Maximum Observed Percent CFB in Peak Vascular Endothelial Growth Factor (VEGF) Upto Week 4
Percent changePlaceboGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mg
Maximum Observed Percent CFB in Peak Vascular Endothelial Growth Factor (VEGF) Upto Week 445.05 (1.00 to 108.32)18.78 (4.38 to 35.17)18.94 (8.19 to 30.75)27.70 (6.07 to 53.73)44.29 (14.44 to 81.94)
SecondaryPercent CFB in Hepcidine Upto Week 4

Blood samples for hepcidine were collected on Day 1 (pre-dose), Week 2 (collected approximately 6-12 hours post-dose) and Week 4 (pre-dose). Baseline was defined as the value on Day 1. Percent CFB was calculated as 100 multiplied by the exponential mean change on a log scale minus 1.

Time frame:
Baseline (Day 1) Upto Week 4
Reported as:
Geometric mean · Percent change
Percent CFB in Hepcidine Upto Week 4
Percent changePlaceboGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mg
Percent CFB in hepcidine,Week 29.98 (-0.66 to 21.76)-50.71 (-59.75 to -39.65)-64.90 (-73.55 to -53.42)-66.29 (-73.38 to -57.30)-73.52 (-78.79 to -66.94)
Percent CFB in hepcidine,Week 43.26 (-9.18 to 17.42)-60.34 (-67.40 to -51.76)-69.66 (-77.38 to -59.30)-69.06 (-77.57 to -57.31)-77.71 (-82.08 to -72.28)
SecondaryCFB in Ferritin at Week 4

Ferritin was used as marker of iron metabolism and utilization. Baseline was defined as the value on Day 1. CFB was calculated by subtracting the Baseline value from the post dose value at Week 4.

Time frame:
Baseline (Day 1) and Week 4
Reported as:
Mean · micrograms/liter
CFB in Ferritin at Week 4
micrograms/literPlaceboGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mg
CFB in Ferritin at Week 44.7 ± 114.79-50.6 ± 40.28-78.3 ± 52.32-92.6 ± 107.07-113.3 ± 94.69
SecondaryCFB in Total Iron Binding Capacity [TIBC], Unbound Iron Binding Capacity [UIBC] and Iron at Week 4

TIBC, UIBC and Iron were used as marker of iron metabolism and utilization. Baseline was defined as the value on Day 1. CFB was calculated by subtracting the Baseline value from the post-dose value at Week 4.

Time frame:
Baseline (Day 1) and Week 4
Reported as:
Mean · micromoles/liter
CFB in Total Iron Binding Capacity [TIBC], Unbound Iron Binding Capacity [UIBC] and Iron at Week 4
micromoles/literPlaceboGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mg
CFB in TIBC at Week 40.2 ± 1.978.6 ± 3.9614.4 ± 6.7914.3 ± 5.6717.2 ± 4.87
CFB in UIBC at Week 40.8 ± 6.1011.7 ± 6.6119.2 ± 9.1716.3 ± 9.1822.1 ± 7.65
CFB in Iron at Week 40.0 ± 4.46-3.1 ± 4.96-4.8 ± 5.86-2.4 ± 7.16-4.9 ± 5.32
SecondaryCFB in Transferrin at Week 4

Transferrin was used as marker of iron metabolism and utilization. Baseline was defined as the value on Day 1. CFB was calculated by subtracting the Baseline value from the post-dose value at Week 4.

Time frame:
Baseline (Day 1) and Week 4
Reported as:
Mean · grams/liter
CFB in Transferrin at Week 4
grams/literPlaceboGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mg
CFB in Transferrin at Week 40.041 ± 0.20130.449 ± 0.29580.626 ± 0.36050.677 ± 0.29480.804 ± 0.3944
SecondaryPercent CFB in Transferrin Saturation (TS) at Week 4

TS was used as marker of iron metabolism and utilization. Baseline was defined as the value on Day 1. Percent CFB was calculated as 100 multiplied by the exponential mean change on a log scale minus 1.

Time frame:
Baseline (Day 1) and Week 4
Reported as:
Geometric mean · Percent change
Percent CFB in Transferrin Saturation (TS) at Week 4
Percent changePlaceboGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mg
Percent CFB in Transferrin Saturation (TS) at Week 41.3 (-10.5 to 14.6)-31.3 (-41.4 to -19.5)-45.3 (-54.9 to -33.8)-35.2 (-50.9 to -14.5)-50.4 (-59.0 to -39.8)
SecondaryPlasma Pharmacokinetic Concentration of GSK1278863 and Metabolites (M) at Week 4

Blood samples for plasma pharmacokinetic analysis were collected at Week 4 (pre-dose, 1, 2, 3 hours post-dose). Individual plasma GSK1278863 and M-GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531401, GSK2531403 concentrations have been presented.

Time frame:
Week 4
Reported as:
Mean · micrograms/liter
Plasma Pharmacokinetic Concentration of GSK1278863 and Metabolites (M) at Week 4
micrograms/literPlaceboGSK1278863 4 Milligrams (mg)GSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mg
GSK1278863,Week 4,Pre-dose—0.051 ± NA0.031 ± NA0.054 ± NA0.767 ± NA
GSK1278863,Week 4,1 hour Post-dose—57.974 ± 86.615844.463 ± 64.555069.804 ± 104.4868105.200 ± 109.5148
GSK1278863,Week 4,2 hour Post-dose—79.718 ± 68.669188.600 ± 97.685290.774 ± 95.5198145.487 ± 148.5738
GSK1278863,Week 4,3 hour Post-dose—47.629 ± 38.034986.753 ± 73.461582.612 ± 91.3694111.182 ± 104.4788
GSK2391220-M,Week 4,Pre-dose—3.023 ± 2.45913.357 ± 1.88195.630 ± 6.29088.553 ± 8.1226
GSK2391220-M,Week 4,1 hour Post-dose—2.105 ± 1.52092.883 ± 1.99244.340 ± 4.06998.417 ± 7.7174
GSK2391220-M,Week 4,2 hour Post-dose—4.596 ± 3.29875.809 ± 4.62079.294 ± 7.684214.017 ± 10.5152
GSK2391220-M,Week 4,3 hour Post-dose—6.444 ± 4.20388.227 ± 4.902411.116 ± 7.531417.216 ± 9.7376
GSK2487818-M,Week 4,Pre dose—0.141 ± NA0.171 ± 0.11930.336 ± 0.61431.714 ± 5.1050
GSK2487818-M,Week 4,1 hour Post-dose—0.838 ± 1.00981.445 ± 1.97731.633 ± 2.49944.967 ± 6.2427
GSK2487818-M,Week 4,2 hour Post-dose—4.005 ± 3.24614.510 ± 4.42906.843 ± 6.494410.749 ± 8.8713
GSK2487818-M,Week 4,3 hour Post-dose—5.548 ± 3.70806.932 ± 4.58918.504 ± 5.929314.311 ± 7.8161
GSK2506102-M,Week 4,Pre-dose—2.016 ± 0.77192.943 ± 1.06694.244 ± 2.80925.670 ± 2.2887
GSK2506102-M,Week 4,1 hour Post dose—1.159 ± 0.62771.705 ± 0.56362.473 ± 1.56563.552 ± 1.7551
GSK2506102-M,Week 4,2 hour Post dose—1.344 ± 0.60151.851 ± 0.86372.781 ± 1.62663.963 ± 2.0477
GSK2506102-M,Week4,3 hour Post dose—1.569 ± 0.74672.163 ± 1.04103.045 ± 1.87904.382 ± 1.9892
GSK2531398-M,Week 4, Pre-dose—0.717 ± 0.53560.772 ± 0.44091.478 ± 1.96812.496 ± 2.9738
GSK2531398-M,Week 4,1 hour Post-dos—0.593 ± 0.42550.828 ± 0.66701.455 ± 1.71742.820 ± 2.8853
GSK2531398-M,Week 4,2 hour Post-dose—1.715 ± 1.39862.141 ± 1.83323.496 ± 3.08185.318 ± 4.1121
GSK2531398-M,Week 4,3 hour Post-dose—2.596 ± 1.56303.328 ± 2.13024.813 ± 3.43156.861 ± 3.7679
GSK2531401-M,Week 4, Pre-dose—6.698 ± 3.934911.849 ± 6.481717.427 ± 11.393419.014 ± 7.8014
GSK2531401-M,Week 4,1 hour Post-dose—3.426 ± 2.04456.383 ± 3.07609.259 ± 6.319811.288 ± 6.2673
GSK2531401-M,Week 4,2 hour Post-dose—3.384 ± 1.69845.546 ± 2.74238.910 ± 5.247711.008 ± 6.8874
GSK2531401-M,Week 4,3 hour Post-dose—3.911 ± 2.34755.849 ± 2.91448.864 ± 6.043311.417 ± 6.2311
GSK2531403-M,Week 4, Pre-dose—5.609 ± 3.64948.183 ± 3.116912.703 ± 10.114416.524 ± 9.9794
GSK2531403-M,Week 4,1 hour Post-dose—3.100 ± 2.05505.093 ± 1.98727.607 ± 5.591311.877 ± 8.2571
GSK2531403-M,Week 4,2 hour Post-dose—4.857 ± 3.17056.906 ± 4.037410.755 ± 7.384115.573 ± 10.2857
GSK2531403-M,Week 4,3 hour Post-dose—6.320 ± 4.15588.744 ± 4.612312.119 ± 7.670218.369 ± 9.0090
SecondaryNumber of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) on Therapy

An AE is defined as any untoward medical occurrence in clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. A SAE is defined as any AE which results in death; is life-threatening; requires participant hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event.

Time frame:
Upto Week 4
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) on Therapy
ParticipantsPlaceboGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mg
Any AE56875
Any SAE10000
SecondaryNumber of Participants With Chemistry and Hematology Data of Potential Clinical Importance (PCI) Upto Week 4

The PCI range was as follows: alkaline phosphates \>= 3 times upper limit of normal range \[ULRR\]), potassium (\>0.5 millimoles/liter below the LLRR or \>1.0 millimoles/liter above the ULRR), phosphate (\>0.323 millimoles/liter above ULRR or below lower limit reference range \[LLRR\]), glucose (\<3.9 or \>22 millimoles/liter), magnesium (\<LLRR or \> 0.3 milimoles/liter above ULRR), lymphocytes \<0.5x LLRR, neutrophils (\<0.5 times LLRR), platelets (80 or \>500 times giga/liter), platelets (80 or \>500 times giga/liter) and leukocytes \>1 x giga/liter below the LLRR or \>5 x GI/L above the ULRR. The participants who had PCI values higher and lower than the reference range have been presented.

Time frame:
Upto Week 4
Reported as:
Count of participants · Participants
Number of Participants With Chemistry and Hematology Data of Potential Clinical Importance (PCI) Upto Week 4
ParticipantsPlaceboGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mg
Alkaline phosphatase, Week 4, High01000
Potassium, High, Week 200010
Potassium, High, Week 410010
Phosphate, High, Week 2191079
Phosphate, High, Week 42911810
Potassium, low, Week 400100
Potassium, low, Week 200100
Glucose, Week 2, low01000
Magnesium, low, Week 400010
Magnesium, low, Week 200010
Lymphocytes, low ,Week 100010
Lymphocytes, low ,Week 300100
Neutrophils, low, Week 101000
Platelets, low, Week 100100
Platelets, low, Week 200100
Platelets, low, Week 300100
Platelets, low, Week 400100
Leukocyte, low, Week 133212
Leukocyte, low, Week 223243
Leukocyte, low, Week 332023
Leukocyte, low, Week 412224
SecondaryNumber of Participants With Vital Signs Parameters Systolic and Diastolic Blood Pressure (SBP,DBP) of PCI Upto Week 4

Vital signs SBP and DBP were recorded pre-dialysis and post-dialysis. Measurements were taken from the participant while in a seated position or semi-supine in the dialysis chair. PCI range for SBP was \< 85 or \> 170 and for DBP was \< 45 or \> 100 millimeters of mercury. Participant's with values high and low from the PCI range have been presented.

Time frame:
Upto Week 4
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs Parameters Systolic and Diastolic Blood Pressure (SBP,DBP) of PCI Upto Week 4
ParticipantsPlaceboGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mg
DBP, high, Pre-dialysis, Week 110101
DBP, high, Pre-dialysis, Week 220102
DBP, high, Pre-dialysis,Week 401000
DBP, high, Post-dialysis, Week 211001
DBP, high, Post-dialysis, Week 300100
DBP, high, Post-dialysis, Week 400100
DBP, low, Post-dialysis, Week 410000
SBP, high, Pre-dialysis, Week 124031
SBP, high, Pre-dialysis, Week 243324
SBP, high, Pre dialysis, Week 323221
SBP, high, Pre-dialysis, Week 426142
SBP, high, Post-dialysis, Week 141011
SBP, high, Post-dialysis, Week 210013
SBP, high, Post-dialysis, Week 320323
SBP, high, Post-dialysis, Week 411123
SBP, low, Post-dialysis, Week 201000
SBP, low, Post-dialysis, Week 410000
SecondaryNumber of Participants With Vital Sign Parameter Heart Rate (HR) of PCI Upto Week 4

Vital sign HR was recorded pre-dialysis and post-dialysis. Measurements were taken from the participant while in a seated position or semi-supine in the dialysis chair. PCI range for HR was \< 40 or \> 110 beats per minute. Participant's with values higher than the PCI range have been presented.

Time frame:
Upto Week 4
Reported as:
Count of participants · Participants
Number of Participants With Vital Sign Parameter Heart Rate (HR) of PCI Upto Week 4
ParticipantsPlaceboGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mg
HR, high, Post-dialysis, Week 100100
HR, high, Post-Dialysis, Week 300100
SecondaryNumber of Participants With Abnormal Electrocardiogram (ECG) Findings Upto Week 4

Full 12-lead ECGs included heart rate, PR, QRS, QT and QTc intervals. Measurements were taken from the participant while in a supine position. ECGs were performed consistently either before or after dialysis throughout the study. ECG abnormalities characterized as abnormal-not clinically significant (A-NCS) and abnormal-clinically significant (A-CS) upto W4 have been presented.

Time frame:
Upto Week 4
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Electrocardiogram (ECG) Findings Upto Week 4
ParticipantsPlaceboGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mg
A-NCS, Week 258677
A-NCS, Week 428586

Adverse events

Collected over AEs were assessed from screening (Week 3-9) throughout the treatment period (4 Week) until follow-up (4 Weeks post the last dose of study medication).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/19 (0%)1/19 (5.3%)4/19 (21.1%)
GSK1278863 4 mg0/19 (0%)0/19 (0%)6/19 (31.6%)
GSK1278863 6 mg0/20 (0%)0/20 (0%)8/20 (40%)
GSK1278863 8 mg0/19 (0%)0/19 (0%)7/19 (36.8%)
GSK1278863 10 mg0/20 (0%)0/20 (0%)5/20 (25%)
Most frequent serious events
Most frequent serious events
EventPlaceboGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mg
Cerebral haemorrhageNervous system disorders1/190/190/200/190/20
Most frequent other events
Showing 10 of 27
Most frequent other events
EventPlaceboGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mg
NasopharyngitisInfections and infestations0/191/190/202/192/20
Upper respiratory tract infectionInfections and infestations0/191/190/200/190/20
DermatitisSkin and subcutaneous tissue disorders1/191/190/201/190/20
Haemorrhage subcutaneousSkin and subcutaneous tissue disorders0/191/190/200/190/20
RashSkin and subcutaneous tissue disorders1/190/190/200/190/20
InjuryInjury, poisoning and procedural complications0/190/190/201/190/20
Procedural hypotensionInjury, poisoning and procedural complications0/191/190/200/190/20
Back painMusculoskeletal and connective tissue disorders0/190/191/201/190/20
Lumbar spinal stenosisMusculoskeletal and connective tissue disorders0/191/190/200/190/20
StomatitisGastrointestinal disorders0/190/190/201/190/20

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mgTotal
Mean63.4 ± 8.9861.6 ± 8.4958.9 ± 9.9066.0 ± 9.2362.2 ± 11.1362.4 ± 9.70
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mgTotal
Female711812947
Male1281271150
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 10 mgTotal
American Indian or Alaska Native000000
Asian191920192097
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White000000
More than one race000000
Unknown or Not Reported000000
08

Study locations

21 sites
  • GSK Investigational Site
    Aichi, 446-0053, Japan
  • GSK Investigational Site
    Aichi, 446-0065, Japan
  • GSK Investigational Site
    Aichi, 454-0932, Japan
  • GSK Investigational Site
    Aichi, 455-0021, Japan
  • GSK Investigational Site
    Aichi, 465-0025, Japan
  • GSK Investigational Site
    Aichi, 470-1201, Japan
  • GSK Investigational Site
    Chiba, 276-0031, Japan
  • GSK Investigational Site
    Fukuoka, 804-0094, Japan
  • GSK Investigational Site
    Ibaraki, 300-0835, Japan
  • GSK Investigational Site
    Ibaraki, 305-0861, Japan
  • GSK Investigational Site
    Ibaraki, 310-0844, Japan
  • GSK Investigational Site
    Kagawa, 761-8024, Japan
  • GSK Investigational Site
    Kanagawa, 216-0007, Japan
  • GSK Investigational Site
    Miyagi, 981-0911, Japan
  • GSK Investigational Site
    Nagano, 390-0821, Japan
  • GSK Investigational Site
    Nagano, 390-1401, Japan
  • GSK Investigational Site
    Niigata, 950-2038, Japan
  • GSK Investigational Site
    Osaka, 543-0052, Japan
  • GSK Investigational Site
    Osaka, 547-0024, Japan
  • GSK Investigational Site
    Tokyo, 158-0094, Japan
  • GSK Investigational Site
    Toyama, 930-0964, Japan
09

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2013 to primary completion in Aug 2014, 9 months.

Results were first posted in Feb 2018, 3 years 6 months after primary completion.

Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's 9 months is below that.

Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2013
First posted
Dec 24, 2013
StartActual
Nov 5, 2013
Primary completionActual
Aug 6, 2014
CompletionActual
Aug 6, 2014
Results first posted
Feb 12, 2018
Last update
Feb 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02019719
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 24, 2013
Start date
Nov 5, 2013
Primary completion
Aug 6, 2014
Completion
Aug 6, 2014
Results posted
Feb 12, 2018
Last update
Feb 12, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK1278863

Start the discussion